Tvardi Therapeutics Income Statement (2013-2025) | TVRD

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025
Revenue & cost
Revenue (Quarter)	1.94M		20.27M	0.82M	4.79M	23.00M	10.81M	3.26M	6.17M	6.93M	4.87M	3.00M	2.13M	0.99M	2.56M	1.46M	2.57M
Cost of Revenue (Quarter)					2.08M		3.06M	2.13M	2.59M	1.42M	1.56M	0.61M	0.62M
Gross Profit (Quarter)					2.71M	23.00M	7.76M	1.13M	3.58M	5.51M	3.31M	2.40M	1.51M	0.99M	2.56M	1.46M
Operating items
Research & Development (Quarter)	19.13M	25.23M	15.51M	22.83M	21.27M	19.91M	24.69M	26.01M	24.33M	30.31M	25.45M	28.41M	21.96M	6.53M	4.79M	8.60M	0.32M	5.81M	3.60M	5.49M
Selling, General & Administrative (Quarter)	6.37M	5.65M	5.88M	11.51M	9.35M	7.57M	6.91M	6.43M	6.89M	7.54M	6.75M	6.59M	6.82M	0.65M	0.88M	2.20M	4.64M	3.06M	2.33M	2.10M
Restructuring Costs (Quarter)													2.40M	0.16M	0.39M	1.61M		2.02M	1.32M	1.25M
Other Operating Expenses (Quarter)					2.08M		3.06M	2.13M	2.59M	1.42M	1.56M	0.61M	0.62M	-0.16M	-0.39M	-1.61M		-2.02M	-1.32M	-1.25M
Operating Expenses (Quarter)	25.50M	30.88M	21.40M	34.34M	32.70M	27.48M	34.66M	34.57M	33.81M	39.27M	33.76M	35.61M	31.80M	7.18M	5.68M	10.80M	4.96M	8.87M	5.94M	7.59M
Operating Income (Quarter)	-23.56M	-30.88M	-1.12M	-33.52M	-27.91M	-4.47M	-23.84M	-31.31M	-27.65M	-32.34M	-28.90M	-32.61M	-29.67M	-7.18M	-5.68M	-10.80M	-2.39M	-8.87M	-5.94M	-7.59M
EBIT (Quarter)	-23.56M	-30.88M	-1.12M	-33.52M	-27.91M	-4.47M	-23.84M	-31.31M	-27.65M	-32.34M	-28.90M	-32.61M	-29.67M	-7.18M	-5.68M	-10.80M	-2.39M	-8.87M	-5.94M	-7.59M
Non-operating items
Interest & Investment Income (Quarter)														0.21M	0.16M	0.13M		0.38M	0.41M	0.31M
Other Non Operating Income (Quarter)	0.26M	0.13M	0.11M	0.14M	0.16M	0.27M	0.67M	0.97M	0.98M	0.86M	0.87M	0.87M	0.95M	0.69M	0.77M	-4.44M	0.35M	12.66M
Non Operating Income (Quarter)	0.26M	0.13M	0.11M	0.14M	0.16M	0.27M	0.67M	0.97M	0.98M	0.86M	0.87M	0.87M	0.95M	0.69M	0.77M	-4.44M	0.35M	12.66M
Net income details
EBT (Quarter)	-23.30M	-30.75M	-1.01M	-33.38M	-27.91M	-4.47M	-23.84M	-31.31M	-27.65M	-32.34M	-28.90M	-32.61M	-29.67M	-6.97M	-5.51M	-10.67M	-2.39M	-8.49M	-5.53M	-7.28M
Tax Provisions (Quarter)
Profit After Tax (Quarter)	-23.30M	-30.75M	-1.01M	-33.38M	-27.75M	-4.21M	-23.18M	-30.34M	-26.66M	-31.48M	-28.03M	-32.34M	-4.20M	-6.97M	-5.51M	-12.71M	-9.58M	4.17M	-5.53M	-7.30M
Income from Continuing Operations (Quarter)	-23.30M	-30.75M	-1.01M	-33.38M	-27.91M	-4.47M	-23.84M	-31.31M	-27.65M	-32.34M	-28.90M	-32.61M	-29.67M	-6.97M	-5.51M	-10.67M	-2.39M	-8.49M	-5.53M	-7.28M
Consolidated Net Income (Quarter)	-23.30M	-30.75M	-1.01M	-33.38M	-27.91M	-4.47M	-23.84M	-31.31M	-27.65M	-32.34M	-28.90M	-32.61M	-29.67M	-6.97M	-5.51M	-10.67M	-2.39M	-8.49M	-5.53M	-7.28M
Income towards Parent Company (Quarter)	-23.30M	-30.75M	-1.01M	-33.38M	-27.91M	-4.47M	-23.84M	-31.31M	-27.65M	-32.34M	-28.90M	-32.61M	-29.67M	-6.97M	-5.51M	-10.67M	-2.39M	-8.49M	-5.53M	-7.28M
Net Income towards Common Stockholders (Quarter)	-23.30M	-30.75M	-1.01M	-33.38M	-27.91M	-4.47M	-23.84M	-31.31M	-27.65M	-32.34M	-28.90M	-32.61M	-29.67M	-6.97M	-5.51M	-10.67M	-2.39M	-8.49M	-5.53M	-7.28M
Additional items
EPS (Basic) (Quarter)	-0.47	-0.61	-0.02	-0.64	-0.52	-0.08	-0.43	-18.09	-0.49	-0.58	-0.52	-24.67	-20.24	-2.71	-2.14	-4.94	-3.22	0.51	-0.59	-0.84
EPS (Weighted Average and Diluted) (Quarter)	-0.47	-0.61	-0.02	-0.64	-0.52	-0.08	-0.43	-18.09	-0.49	-0.58	-0.52	-24.67	-20.24	-2.71	-2.14	-4.94	-3.22	-1.00	-0.59	-0.76
Shares Outstanding (Weighted Average) (Quarter)	49.92M	50.06M	50.11M	50.72M	53.51M	53.61M	53.62M	4.47M	53.87M	54.00M	54.04M	4.51M	1.52M	54.66M	54.72M	2.57M	1.52M	8.25M	9.38M	7.42M
Shares Outstanding (Diluted Average) (Quarter)	49.92M	49.99M	50.11M	50.72M	53.51M	53.56M	53.62M	4.47M	53.87M	53.94M	54.04M	4.51M	1.52M	54.66M	54.84M	4.56M	1.52M
EBITDA (Quarter)	-23.36M	-30.76M	-1.01M	-33.74M	-29.11M	-4.53M	-23.28M	-29.86M	-26.09M	-31.11M	-27.74M	-32.16M	-30.63M	-6.97M	-5.51M	-12.71M	-4.91M	4.15M	-5.51M	-7.27M
Tax Rate (Quarter)

Research Tools

Tvardi Therapeutics Income Statement (2013-2025) | TVRD

Create an account

Sign In

Reset Password